Cromatina/Epigenética
Os inibidores de cromatina/epigenética são compostos que modulam a estrutura e função da cromatina ou interferem em modificações epigenéticas, como a metilação do DNA e a modificação de histonas. Esses inibidores são ferramentas essenciais para estudar a regulação da expressão gênica e o papel da epigenética em doenças como o câncer, distúrbios neurológicos e anomalias do desenvolvimento. Ao direcionar os processos epigenéticos, esses inibidores podem alterar os padrões de expressão gênica e oferecer novas vias terapêuticas. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de cromatina/epigenética de alta qualidade para apoiar sua pesquisa em biologia molecular, genética e epigenética.
Subcategorias de "Cromatina/Epigenética"
Foram encontrados 2242 produtos de "Cromatina/Epigenética"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
JAK-STAT Compound Library
<p>A unique collection of 252 JAK/STAT signaling targeted compounds for high throughput and high content screening;</p>Cor e Forma:Odour Solid3β,6α,12β-Dammar-E-20(22)-ene-3,6,12,25-tetraol
CAS:<p>3β,6α,12β-Dammar-E-20(22)-ene-3,6,12,25-tetraol is a compound that functions as a SIRT1 activator, effectively enhancing SIRT1 activity.</p>Fórmula:C30H52O4Cor e Forma:SolidPeso molecular:476.742ACBI2
CAS:<p>ACBI2: potent, oral VHL PROTAC, EC50=7nM; degrades SMARCA2, DC50=1nM in RKO cells; for lung cancer research.</p>Fórmula:C56H68BrFN8O5SCor e Forma:SolidPeso molecular:1064.16Ep300/CREBBP-IN-8
CAS:<p>Ep300/CREBBP-IN-8, IC50: 0.014/0.018 μM, potent Ep300/CREBBP inhibitor, oral, for cancer research.</p>Fórmula:C25H27F2N5O3Cor e Forma:SolidPeso molecular:483.51LLY-284
CAS:<p>LLY-284, a less active PRMT5 inhibitor diastereomer of LLY-283, serves as its negative control.</p>Fórmula:C17H18N4O4Pureza:98%Cor e Forma:SolidPeso molecular:342.35Aclantate
CAS:<p>Aclantate is a nonsteroidal anti-inflammatory drug.</p>Fórmula:C15H14ClNO4SPureza:98%Cor e Forma:SolidPeso molecular:339.79SRG-II-19F
<p>SRG-II-19F is a BRDT BD1 degrader, useful for studying ClpC2's impact on ClpC1P1P2 protease.</p>Fórmula:C80H109ClN16O14SCor e Forma:SolidPeso molecular:1586.34HDAC6-IN-53
<p>HDAC6-IN-53 (Compound W28) is an inhibitor targeting histone deacetylase 6 (HDAC6) with an IC50 of 19.65 nM. It reduces the idiopathic pulmonary fibrosis (IPF) phenotype by inhibiting TGF-β1-induced collagen expression and demonstrates therapeutic efficacy in a bleomycin-induced mouse model of pulmonary fibrosis. HDAC6-IN-53 is applicable for research in idiopathic pulmonary fibrosis and related pulmonary fibrotic diseases.</p>Cor e Forma:Odour SolidSAMS
CAS:<p>SAMS peptide is a specific substrate for the AMP-activated protein kinase (AMPK).</p>Fórmula:C74H131N29O18S2Pureza:98%Cor e Forma:SolidPeso molecular:1779.15Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)
CAS:<p>Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide derived from mouse JAK2, specifically composed of amino acids 475 to 491.</p>Fórmula:C88H138N20O34P2Pureza:98%Cor e Forma:SolidPeso molecular:2082.1CPI-1328
CAS:<p>CPI-1328 is an EZH2 inhibitor with a K i value of 63 fM.</p>Fórmula:C28H36ClN3O4SCor e Forma:SolidPeso molecular:546.12NPC-15437 dihydrochloride
CAS:<p>NPC-15437 dihydrochloride is a PKC inhibitor blocking enzyme activity and phorbol ester binding, selective over other kinases, in cellular signaling research.</p>Fórmula:C25H52Cl2N4O2Cor e Forma:SolidPeso molecular:511.62PROTAC BRD9-binding moiety 1
CAS:<p>PROTAC BRD9-binding moiety 1 that binds to BRD9, and used for inhibiting BRD9 activity, based on PROTAC.</p>Fórmula:C23H25N3O7S2Pureza:98%Cor e Forma:SolidPeso molecular:519.59DNMT1/HDAC-IN-1
<p>DNMT1/HDAC-IN-1 (compound (R)-23a), a potent dual inhibitor targeting both DNMT1 and HDAC, exhibits impressive inhibitory effects specifically on HDAC1 (HDAC1:IC50=0.05 μM), a major HDAC isoform that interacts with DNMT1 across multiple protein complexes involved in the transcriptional silencing of TSGs. This compound has been shown to remodel the tumor immune microenvironment and induce tumor regression, effectively reversing cancer-specific epigenetic abnormalities.</p>Cor e Forma:Odour SolidPROTAC BRD4-DCAF1 degrader-1
CAS:<p>PROTACBRD4-DCAF1 degrader-1 (I-907) is a PROTAC degrader targeting BRD4-DCAF1, exhibiting a DC50 range of 10~100 nM.</p>Fórmula:C60H64Cl2F2N8O9SCor e Forma:SolidPeso molecular:1182.17Ep300/CREBBP-IN-3
CAS:<p>Ep300/CREBBP-IN-3 inhibits Ep300 & CREBBP (IC50: 0.056 & 0.095 μM respectively); potential for cancer research.</p>Fórmula:C26H25F4N5O3Cor e Forma:SolidPeso molecular:531.50Malantide TFA
<p>Malantide TFA: synthetic dodecapeptide, PKA-specific with Km 15 μM, >90% PKI blockage, also PKC substrate, Km 16 μM.</p>Fórmula:C74H125F3N22O23Cor e Forma:SolidPeso molecular:1747.91PRMT5-IN-41
CAS:PRMT5-IN-41 (compound 130) is an effective orally active inhibitor of PRMT5. It inhibits the hERG ion channel with an IC50 of 1.36 µM.Fórmula:C22H16F5N5O2Peso molecular:477.39PROTAC SMARCA2/4-degrader-28
CAS:<p>PROTAC SMARCA2/4-degrader-28 (PROTAC 1) functions as a partial degrader of SMARCA2 and SMARCA4 through the PROTAC-based mechanism.</p>Fórmula:C54H68ClN9O11S2Cor e Forma:SolidPeso molecular:1118.75Dot1L-IN-1 TFA
<p>Dot1L-IN-1 TFA: potent inhibitor, K i =2 pM, IC 50 <0.1 nM; reduces H3K79 dimethylation (IC 50 =3 nM) & HoxA9 promoter activity (IC 50 =17 nM).</p>Fórmula:C34H37ClF3N9O4SCor e Forma:SolidPeso molecular:760.23
